This new agent, like the other DPP-4 inhibitors, has a mechanism of action that affects both pancreatic ß-cell survival as well as ß-cell secretory function. These medications do not incite ...

This is the first approved agent in a new class of antihyperglycemics, dipeptidyl peptidase (DPP)-4 inhibitors ... action, including T-cell activation and proliferation. Although the mechanism ...

Atherosclerotic cardiovascular disease is a major health concern worldwide and requires effective preventive measures. Lp(a) (lipoprotein [a]) has recently garnered attention as an independent risk ...

Both SLGT2 inhibitors and GLP-1s lowered moderate or severe COPD exacerbation risk vs. DPP-4 inhibitors. Weight loss and SGLT2 inhibitors’ glucosuria effect may explain the findings. Sodium ...

In adults with type 2 diabetes and active COPD, the risk of moderate or severe COPD exacerbation was 14-19% lower with the two classes as compared with DPP-4 inhibitors, reported researchers led ...

Cell cycle re-entry of senescent breast cancer cells after CDK4/6 inhibition (CDK4/6i) constitutes a major source of disease ...

The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of ...

Immune checkpoint inhibitors (ICIs) have transformed cancer therapy by targeting key immune pathways such as PD-1, PD-L1, CTLA-4, and LAG-3 to enhance the immune system's ability to combat ...

Despite the established links between inflammation and cancer development, the effects of inflammatory signaling on cancer ...

Given the success of the previous Research Topic 'Exploring Small Molecule Inhibitors in Cardiovascular and Cerebrovascular Diseases', we are pleased to ...

In this Research Topic, we explore recent work about the pharmacological effects such as immunological, anti-tumor, anti-oxidant, anti-inflammatory, hypoglycemic, antibacterial, hepatoprotective ...

Frank Cottrell-Boyce and Cressida Cowell recommend a selection of children’s books.